Patients' expression of CEACAM5 might hold the key to activity after all.

The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.

Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

After Niagara the company faces three pivotal catalysts; none is a slam-dunk.

The group eyes a broader use than Immunocore’s Kimmtrak.

A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.